SG11201704542SA - 4,6-SUBSTITUTED-PYRAZOLO[1,5-a]PYRAZINES AS JANUS KINASE INHIBITORS - Google Patents

4,6-SUBSTITUTED-PYRAZOLO[1,5-a]PYRAZINES AS JANUS KINASE INHIBITORS

Info

Publication number: SG11201704542SA
Authority: SG; Singapore
Prior art keywords: pyrazines; pyrazolo; substituted; kinase inhibitors; janus kinase
Prior art date: 2014-12-05

Application number

SG11201704542SA

Inventor

Shelley Allen

Mark Laurence Boys

Mark J Chicarelli

Jay Bradford Fell

John P Fischer

John Gaudino

Erik James Hicken

Ronald Jay Hinklin

Christopher F Kraser

Ellen Laird

John E Robinson

Tony P Tang

Laurence E Burgess

Robert Andrew Rieger

Jed Pheneger

Yoshitaka Satoh

Katerina Leftheris

Raj K Raheja

Brydon L Bennett

Original Assignee

Array Biopharma Inc

Celgene Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-12-05

Filing date

2015-12-04

Publication date

2017-07-28

2015-12-04 Application filed by Array Biopharma Inc, Celgene Corp filed Critical Array Biopharma Inc

2017-07-28 Publication of SG11201704542SA publication Critical patent/SG11201704542SA/en

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

SG11201704542SA 2014-12-05 2015-12-04 4,6-SUBSTITUTED-PYRAZOLO[1,5-a]PYRAZINES AS JANUS KINASE INHIBITORS SG11201704542SA (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201462088068P	2014-12-05	2014-12-05
PCT/US2015/064062 WO2016090285A1 (en)	2014-12-05	2015-12-04	4,6-SUBSTITUTED-PYRAZOLO[1,5-a]PYRAZINES AS JANUS KINASE INHIBITORS

Publications (1)

Publication Number	Publication Date
SG11201704542SA true SG11201704542SA (en)	2017-07-28

Family

ID=55069089

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SG11201704542SA SG11201704542SA (en)	2014-12-05	2015-12-04	4,6-SUBSTITUTED-PYRAZOLO[1,5-a]PYRAZINES AS JANUS KINASE INHIBITORS

Country Status (29)

Country	Link
US (3)	US10189845B2 (en)
EP (2)	EP3878451A1 (en)
JP (2)	JP6641373B2 (en)
KR (1)	KR20170090476A (en)
CN (1)	CN107278203B (en)
AU (1)	AU2015357585B2 (en)
BR (1)	BR112017011798A2 (en)
CA (1)	CA2969709A1 (en)
CL (1)	CL2017001422A1 (en)
CO (1)	CO2017006674A2 (en)
CR (1)	CR20170309A (en)
DK (1)	DK3227297T3 (en)
ES (1)	ES2865483T3 (en)
HR (1)	HRP20210501T1 (en)
HU (1)	HUE054371T2 (en)
IL (1)	IL252656A0 (en)
MX (1)	MX2017007284A (en)
MY (1)	MY191016A (en)
PH (1)	PH12017501032A1 (en)
PL (1)	PL3227297T3 (en)
PT (1)	PT3227297T (en)
RS (1)	RS61693B1 (en)
RU (2)	RU2021102805A (en)
SG (1)	SG11201704542SA (en)
SI (1)	SI3227297T1 (en)
TW (1)	TWI725004B (en)
UA (1)	UA120065C2 (en)
WO (1)	WO2016090285A1 (en)
ZA (1)	ZA201704494B (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2017156493A1 (en)	2016-03-11	2017-09-14	Denali Therapeutics Inc.	Compounds, compositions, and methods
SG11201704542SA (en)	2014-12-05	2017-07-28	Array Biopharma Inc	4,6-SUBSTITUTED-PYRAZOLO[1,5-a]PYRAZINES AS JANUS KINASE INHIBITORS
EP3712153B1 (en) *	2016-02-24	2021-12-01	Pfizer Inc.	Pyrazolo[1,5-a]pyrazin-4-yl derivatives as jak-inhibitors
RS62868B1 (en)	2016-06-16	2022-02-28	Denali Therapeutics Inc	Pyrimidin-2-ylamino-1h-pyrazols as lrrk2 inhibitors for use in the treatment of neurodegenerative disorders
GB201617758D0 (en) *	2016-10-20	2016-12-07	Almac Discovery Limited	Pharmaceutical compounds
EP3571203B1 (en)	2017-01-18	2023-06-07	Array BioPharma Inc.	Substituted pyrazolo[1,5-a]pyrazine compounds as ret kinase inhibitors
WO2018217946A1 (en) *	2017-05-24	2018-11-29	Denali Therapeutics Inc.	Compounds, compositions and methods
US11254668B2 (en)	2017-08-14	2022-02-22	Pfizer Inc.	Pyrazolo[1,5-A]pyrazin-4-yl and related derivatives
US11472802B2 (en)	2018-01-18	2022-10-18	Array Biopharma Inc.	Substituted pyrazolyl[4,3-c]pyridine compounds as RET kinase inhibitors
JP7061195B2 (en)	2018-01-18	2022-04-27	アレイバイオファーマインコーポレイテッド	Substituted pyrazolo [3,4-d] pyrimidine compound as a RET kinase inhibitor
CN111971286B (en)	2018-01-18	2023-04-14	阿雷生物药品公司	Substituted pyrrolo [2,3-d ] pyrimidine compounds as RET kinase inhibitors
WO2020055672A1 (en)	2018-09-10	2020-03-19	Array Biopharma Inc.	Fused heterocyclic compounds as ret kinase inhibitors
EP3954689B1 (en) *	2019-04-12	2024-04-24	Primegene (Beijing) Co., Ltd.	Pyrazolopyrazine derived compounds, pharmaceutical composition and use thereof
JP7137696B2 (en)	2019-05-14	2022-09-14	プロヴェンション・バイオ・インコーポレイテッド	Methods and compositions for preventing type 1 diabetes
CN113150012B (en) *	2020-01-22	2023-03-24	浙江海正药业股份有限公司	Pyrazolo [1,5-a ] pyrazine derivative and preparation method and application thereof
KR20220164008A (en)	2020-04-04	2022-12-12	화이자 인코포레이티드	how to treat coronavirus disease 2019
WO2023083200A1 (en) *	2021-11-12	2023-05-19	南京明德新药研发有限公司	Pyrazolo fused ring compound and use thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6313129B1 (en)	1998-08-21	2001-11-06	Hughes Institute	Therapeutic compounds
DE102007032349A1 (en)	2007-07-11	2009-01-15	Bayer Healthcare Ag	Imidazo, pyrazolopyrazines and imidazotriazines and their use
SI2516434T1 (en)	2009-12-23	2015-10-30	Takeda Pharmaceutical Company Limited	Fused heteroaromatic pyrrolidinones as syk inhibitors
CA2787714C (en) *	2010-01-22	2019-04-09	Joaquin Pastor Fernandez	Inhibitors of pi3 kinase
UY33213A (en) *	2010-02-18	2011-09-30	Almirall Sa	PIRAZOL DERIVATIVES AS JAK INHIBITORS
US20110241987A1 (en) *	2010-04-01	2011-10-06	Smart Technologies Ulc	Interactive input system and information input method therefor
AU2011240808B2 (en) *	2010-04-14	2015-01-22	Array Biopharma Inc.	5, 7-substituted-imidazo [1, 2-c] pyrimidines as inhibitors of JAK kinases
MX2014004473A (en) *	2011-10-12	2015-04-14	Array Biopharma Inc	5,7-substituted-imidazo[1,2-c]pyrimidines.
ES2585044T3 (en) *	2012-03-28	2016-10-03	Merck Patent Gmbh	Bicyclic Pyrazinone Derivatives
SG11201704542SA (en)	2014-12-05	2017-07-28	Array Biopharma Inc	4,6-SUBSTITUTED-PYRAZOLO[1,5-a]PYRAZINES AS JANUS KINASE INHIBITORS

2015
- 2015-12-04 SG SG11201704542SA patent/SG11201704542SA/en unknown
- 2015-12-04 JP JP2017529681A patent/JP6641373B2/en not_active Expired - Fee Related
- 2015-12-04 AU AU2015357585A patent/AU2015357585B2/en not_active Ceased
- 2015-12-04 WO PCT/US2015/064062 patent/WO2016090285A1/en active Application Filing
- 2015-12-04 PT PT158199331T patent/PT3227297T/en unknown
- 2015-12-04 EP EP21152373.3A patent/EP3878451A1/en not_active Withdrawn
- 2015-12-04 CN CN201580066136.5A patent/CN107278203B/en not_active Expired - Fee Related
- 2015-12-04 CR CR20170309A patent/CR20170309A/en unknown
- 2015-12-04 US US15/532,937 patent/US10189845B2/en active Active
- 2015-12-04 PL PL15819933T patent/PL3227297T3/en unknown
- 2015-12-04 EP EP15819933.1A patent/EP3227297B1/en active Active
- 2015-12-04 RS RS20210415A patent/RS61693B1/en unknown
- 2015-12-04 RU RU2021102805A patent/RU2021102805A/en unknown
- 2015-12-04 MY MYPI2017702034A patent/MY191016A/en unknown
- 2015-12-04 BR BR112017011798A patent/BR112017011798A2/en not_active IP Right Cessation
- 2015-12-04 RU RU2017123387A patent/RU2742938C2/en active
- 2015-12-04 HU HUE15819933A patent/HUE054371T2/en unknown
- 2015-12-04 CA CA2969709A patent/CA2969709A1/en not_active Abandoned
- 2015-12-04 KR KR1020177018122A patent/KR20170090476A/en unknown
- 2015-12-04 MX MX2017007284A patent/MX2017007284A/en unknown
- 2015-12-04 UA UAA201707008A patent/UA120065C2/en unknown
- 2015-12-04 SI SI201531544T patent/SI3227297T1/en unknown
- 2015-12-04 DK DK15819933.1T patent/DK3227297T3/en active
- 2015-12-04 ES ES15819933T patent/ES2865483T3/en active Active
- 2015-12-04 TW TW104140878A patent/TWI725004B/en not_active IP Right Cessation
2017
- 2017-06-02 PH PH12017501032A patent/PH12017501032A1/en unknown
- 2017-06-04 IL IL252656A patent/IL252656A0/en active IP Right Grant
- 2017-06-05 CL CL2017001422A patent/CL2017001422A1/en unknown
- 2017-06-30 CO CONC2017/0006674A patent/CO2017006674A2/en unknown
- 2017-07-03 ZA ZA2017/04494A patent/ZA201704494B/en unknown
2018
- 2018-12-06 US US16/212,493 patent/US10730880B2/en active Active
2019
- 2019-12-11 JP JP2019223760A patent/JP2020055859A/en active Pending
2020
- 2020-06-02 US US16/890,663 patent/US11028093B2/en active Active
2021
- 2021-03-29 HR HRP20210501TT patent/HRP20210501T1/en unknown

Also Published As

Publication number	Publication date
AU2015357585B2 (en)	2020-07-02
US10730880B2 (en)	2020-08-04
DK3227297T3 (en)	2021-04-06
US10189845B2 (en)	2019-01-29
WO2016090285A1 (en)	2016-06-09
US20190177328A1 (en)	2019-06-13
EP3878451A1 (en)	2021-09-15
CR20170309A (en)	2018-02-02
PH12017501032A1 (en)	2017-11-27
HUE054371T2 (en)	2021-09-28
RU2017123387A (en)	2019-01-11
MX2017007284A (en)	2017-08-25
KR20170090476A (en)	2017-08-07
RU2017123387A3 (en)	2019-06-03
TWI725004B (en)	2021-04-21
JP6641373B2 (en)	2020-02-05
JP2020055859A (en)	2020-04-09
US11028093B2 (en)	2021-06-08
ES2865483T3 (en)	2021-10-15
US20200291039A1 (en)	2020-09-17
UA120065C2 (en)	2019-09-25
TW201632523A (en)	2016-09-16
SI3227297T1 (en)	2021-04-30
HRP20210501T1 (en)	2021-05-14
EP3227297B1 (en)	2021-01-20
EP3227297A1 (en)	2017-10-11
MY191016A (en)	2022-05-28
IL252656A0 (en)	2017-07-31
CO2017006674A2 (en)	2017-10-20
ZA201704494B (en)	2022-03-30
CN107278203B (en)	2020-05-19
AU2015357585A1 (en)	2017-07-13
CA2969709A1 (en)	2016-06-09
US20170362240A1 (en)	2017-12-21
JP2018507167A (en)	2018-03-15
PL3227297T3 (en)	2021-10-25
CN107278203A (en)	2017-10-20
PT3227297T (en)	2021-04-09
RU2742938C2 (en)	2021-02-11
CL2017001422A1 (en)	2018-01-05
BR112017011798A2 (en)	2017-12-26
RS61693B1 (en)	2021-05-31
RU2021102805A (en)	2021-02-12

Publication	Publication Date	Title
ZA201704494B (en)	2022-03-30	4,6-substituted-pyrazolo[1,5-a]pyrazines as janus kinase inhibitors
HK1258905A1 (en)	2019-11-22	Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
IL277576A (en)	2020-11-30	Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
IL265918A (en)	2019-06-30	Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
ZA201901034B (en)	2021-06-30	Macrocycle kinase inhibitors
IL252053A0 (en)	2017-07-31	תרכובות מותמרות של פירזולו(1, 5-a)פירימידינים ושימוש שלהן בטיפול בהפרעות רפואיות
IL254224A0 (en)	2017-10-31	7-substituted-5-alkyl-[1,2,4] triazolo[1,5-a]pyrimidine derivatives as pde2 inhibitors
HUE050842T2 (en)	2021-01-28	Janus kinase inhibitor
IL290419A (en)	2022-04-01	Imidazo [1,5-a] pyrazine derivatives as pi3kdelta inhibitors
IL252986A0 (en)	2017-08-31	3,5-diaminopyrazole kinase inhibitors